OSUR - OraSure Technologies Inc

https://www.orasure.com

Hold Momentum: Bearish

Recent News

Targeted Genomics Announces Commercial Collaboration with OraSure Technologies for Direct to Consumer ( DTC ) Celiac Genetic Testing - OraSure Technologies ( NASDAQ:OSUR )

Benzinga • 4 months ago • score: 0.19

IRVINE, Calif., May 14, 2025 ( GLOBE NEWSWIRE ) -- Targeted Genomics LLC, developer of GlutenID, the first and only U.S. Food and Drug Administration ( FDA ) cleared direct-to-consumer ( DTC ) test for celiac disease genetics, today announced a commercial collaboration with OraSure Technologies, ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

OraSure Technologies, Inc. develops, manufactures, markets, and sells oral fluid diagnostic products and sample collection devices in the United States, Europe, and internationally. The company is headquartered in Bethlehem, Pennsylvania.

52W High

$4.60

52W Low

$2.36

MA Status:

50D: Above 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.44

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

2.22

EV/Revenue (<3 favorable)

0.11

P/S (TTM) (<3 favorable)

1.71

P/B (<3 favorable)

0.62

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

4.91%

Institutions (25–75% balanced)

90.57%

Shares Outstanding

73,137,000

Float

69,482,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

138,533,000

Gross Profit (TTM)

56,340,000

EPS (TTM)

-0.68

Profit Margin (>10% good)

-0.37%

Operating Margin (TTM) (higher better)

-0.55%

ROE (TTM) (>15% strong)

-0.13%

EPS YoY (Quarterly) (>10% good)

0.30

Revenue YoY (Quarterly) (>8% good)

-0.43

Momentum

Bearish momentum

Value

0.0915

0.0917

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025